News
-
Pharmaxis has announced that its pivotal Phase 3 trial of Bronchitol mannitol DPI in adult patients with cystic fibrosis met its primary endpoint of change in FEV1 from baseline over the 26-week treatment period; however… Read more . . .
-
Windtree Therapeutics has signed an agreement with Hong-Kong based Lee’s Pharmaceutical Limited for the development and commercialization of Aerosurf and other KL4 surfactant products in a number of Asian countries, the company said. Lee’s will… Read more . . .
-
German biotech Ventaleon, a spin-off of Activaero, which was acquired by Vectura in 2014, presented data from a Phase 2 trial of inhaled D, L-lysine acetylsalicylate glycine (LASAG) in severe influenza at the recent ISAM… Read more . . .
-
Smartinhaler manufacturer Adherium Limited has appointed Arik Anderson as Group CEO, the company said. He succeeds company founder Garth Sutherland, who will stay on as an Executive Director on the board. Anderson, who was most… Read more . . .
-
Dr. Reddy’s subsidiary Promius Pharma has announced that a Phase 2 study of its DFN-02 intranasal sumatriptan for the treatment of migraine met its primary endpoint, the proportion of subjects free of migraine pain at… Read more . . .
-
The Grünenthal Group will acquire rights to all dosage forms of Zomig zolmitriptan for the treatment of migraines and cluster headaches, including Zomig nasal spray, from AstraZeneca for $200 million up front plus up to… Read more . . .
-
InCarda Therapeutics has announced that a Phase 1 study of InRhythm inhaled flecainide, which it is developing for the treatment of paroxysmal atrial fibrillation (PAF), met its primary and secondary endpoints, with all doses found… Read more . . .
-
Aptar Pharma has transferred manufacturing equipment for its Child-Resistant and Senior-Friendly Classic Nasal Pump from a plant in Germany to its facility in Congers, NY, the company said. According to Aptar, its child-resistant pump is… Read more . . .
-
Egalet Corporation has announced that Ascend Therapeutics will begin co-promoting Egalet’s Sprix ketorolac tromethamine nasal spray to women’s healthcare practitioners in the US in the third quarter of 2017 and will continue for at least… Read more . . .
-
Device company Nemera has announced a partnership with the Research Center for Respiratory Diseases (CEPR) at the University of Tours for investigation of a novel intranasal drug delivery method. Nemera, which was formerly known as… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.